I Need ONE Response Per Each Discussion Total 6 Responses. Attached Are The Discussions And Rubric Please Follow Them. Posts Will Be A Minimum Of 100 Words, APA Format.One Reference Per Each Discussion
butterflyl
week14.docxRobert Alonso
Accelerated Drug Acquiescence Process
“Fast track” is a procedure devised to ease the evolution, and speed up the analysis of medications to the nurse critical conditions and satisfy unfulfilled medical want. Filling an unfulfilled medical want refers to offering treatment where there is none or offering treatment that might be potentially superior to available treatment. The aim is to get significant novel medicines to the victim earlier. If available treatments exist, a fact medicine must display some benefits over the available treatments such as the capacity to attend to emerging public health count. This essay will discuss the procedures and regulations of fast track and the medical conditions that warrant the use of fast track drugs.
New drugs are being developed daily through a robust procedure known as the drug invention process (Arulsamy et al., 2016). The process of the fast track involves the following steps first, a drug company requests for fast track designation. This appeal may be instituted at whatever time throughout the medication evaluation procedure. Secondly, the appeal is reviewed and a decision is established within two months based on whether the medicine fulfills an unsatisfied medical want in a critical condition. Fast track is regulated once a medicine receives the designation. The rate at which communication occurs guarantees quick solving of questions and problems frequently, resulting in earlier approval of drugs and their availability to patients.
Fast track attends to a wide range of critical medical conditions. Deciding if a condition is critical is a subject of discernment, but in general, this decision is based on whether the medication will affect elements like survival or the possibility that the condition if not treated, will advance from a slightly serious condition to a more severe one. Fast track drugs are used in treating life menacing diseases (Kesselheim et al., 2015). Some of the medical conditions that permit the use of fast track drugs include cancer, epilepsy, heart failure, diabetes, Alzheimer’s and depression.
In conclusion, the essay discussed the procedures and regulations of fast track and the medical conditions that warrant the use of fast track drugs. Any medications have been evolved to nurse or avert a condition that lacks current treatment is clearly aimed at unfulfilled need. Untimely and persistent communication between the drug firm and FDA is recommended throughout the whole drug evolution and evaluation process.
References
Arulsamy, A., Kumari, Y., & Shaikh, M. F. (2016). Reverse pharmacology: fast track path of drug discovery. Pharm Pharmacol Int J, 4(3), 00077.
Kesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015). Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BmJ, 351, h4633.
Ariel Lopez
1) Discuss the process and regulations of Fast Track.
Fast track is an an initiative by an agency in the United States known as Food and Drug Administration (FDA) to investigate drugs for expedited review to enable the development of drugs that would cure acute diseases as well as fill in the unmet gaps in the medicinal field. The process of approving a drug to be consumed by human beings take up to twelve years in the early laboratory.
In the case of the process of approving and expediting Fast Track drugs, different programs are put in place to review the purpose and efficiency of the drugs in the subject. One of the major programs that are essential during the development of Fast Track, drugs is conducting an in-depth study and understanding of the project so that it follows an effective path before approval (Kesselheim et al., 2015). Accelerated approvals may also be conducted upon agreement between the drug sponsors with FDA. Some of the agreements that may be made before this type of approval are based on the unmet needs present to a demographic in the subject, surrogate endpoints that will be scrutinized, the benefits that the drug will have to the patient population being studied as well as post-marketing commitments.
Identify which medical conditions warrant the use of “Fast Track” drugs.
The use of fast-track drugs is warranted under different conditions. One of the medical conditions that can warrant the use of fast-track drug is when there is a serious condition in a particular demographic (Hwang, Darrow & Kesselheim, 2017). Therefore, if there are any positive impacts of using a fast-track drug will lead to the approval of administering the cure. The approval may be looked under two circumstances. One of the circumstances is the survival factor that the drug will offer while the other is preventing the disease in the subject from worsening (Hwang, Darrow & Kesselheim, 2017). Similarly, a fast-track drug may be warranted if there is an unmet medical need. Therefore, people will be allowed to take a fast track drug if it will treat them or prevent them from contacting a particular disease.
In conclusion, Fast Track drugs follow a strict path before being approved to be used. This is done to avoid any health risks that may befall the public by using a fast track drug. Therefore, the FDA makes life-saving investigational drug therapies by offering expedited drug approval. The process is what is identified as Fast Track in the paper. Basically, fast track drugs pass through reviews before being warranted to be used by people who suffer or want to be prevented from a particular disease.References
Hwang, T. J., Darrow, J. J., & Kesselheim, A. S. (2017). The FDA’s expedited programs and clinical development times for novel therapeutics, 2012-2016. Jama, 318(21), 2137-2138. Retrieved from https://jamanetwork.com/journals/jama/fullarticle/2664989
Kesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015). Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: coh
Idalmis Lopez
Process and Regulations of Fast Track
According to Karch (2019), a fast track process is created to ensure the critical unmet needs of patients are met; in case of any critical medical conditions, the system accelerates the FDA review of drugs, and it facilitates the drug development. Therefore, the company must request the designation of the fast track. At any time during the development process, the request can be initiated. After that, following FDA guidelines and rules, the application is analyzed and informed decision made with 60 days on condition that the drug to be released must meet the unmet needs of the patient’s critical condition (Karch, 2019). Throughout the drug development and review process, communication is encouraged between the drug company and the FDA upon receiving fast track designation.
The medical conditions that warrant the use of “Fast Track” drugs
Upon completion of drug review in the last phase of clinical studies, the fast track process authorizes the marketing of the drug. At this point, it is advisable to shorten the approval process of drugs when the life status of a patient is in a critical state. This means it is acceptable to shorten the process to save the life of people who are in dire need of these drugs. Likewise, it is absolutely necessary to approve FDA drugs even in situations when the condition of the patient is not chronically ill or severely diseased. Therefore, it is essential to have the approval of FDA drugs in the cosmetic and food industry because consumer’s life would be at risk if the regulations and strict measures of fast track would not exist (Hawthorne, 2016). Overall, stringent regulations measures for FDA drug approval should apply to everyone. Thus, in critical medical situations, faster approval of FDA drugs is recommended to provide a better chance at life or quality of life.
References
Karch, A. M. (2019). Focus on nursing pharmacology. Lippincott Williams & Wilkins.
Hawthorne, M. (2016). Drug approvals to be put on the fast-track. Australian Medicine, 28(8B), 11.
Daylamis Gonzalez
Fast Track Process and Regulations
Fast track is a process that has been approved and designed by the FDA for purposes of expediting the development and review process of drugs which show a great deal of substantial development over a series of available therapy. Also, the fast track has accelerated the process of drug reviewal to treat severe conditions much earlier, thereby fulfilling an unmet medical need. Determination of the severity of a state depends solely on the mere judgement. Still, it can also be identified by analyzing the effects of the drug on the impacts, e.g. survival and day to day conditions of the patient. Severity determination can also be determined by checking whether leaving the disease untreated will lead to its progression from less severe illness to a much more adverse one. E.g. Aids, Cancer, among other ailments. Using this technicality and methodology, the fast track can identify which medical conditions to allow fast track of their drugs.
Fast track is aimed at fulfilling an unmet medical need which in turn refers to providing a therapy option where none was existing before or providing one that is by far much better. The fast track should show a significant advantage over existing therapies, e.g. is should show superior effectiveness and improved effects of any severe outcomes. Also, the drug should avoid any possible serious side effects of the available therapy; it should also improve on the diagnosis process of a critical condition as well as be able to decrease the available toxicity of the available treatment (FDA, 2020).
Fast track designation is supposed to be requested by the drug manufacturing company. The request process can be initiated at any stage of the drug development process. The FDA then carries put an evaluation and a review of the request and then arrives at a decision and communicates it within the next sixty days. The choice is based on the possibility of the drug fulfilling an unmet medical need. Once the drug has been approved for Fast track, regular communication must be exchanged between the FDA and the drug company to offer more clarity and ensure that all issues and questions are quickly resolved increasing the probability of easy patient conviction to try out the drug.
Fast track designation regulates that the drug-using this method hold many regular meetings with FDA to discuss various issues relating to the drug development prices as well as issues relating to appropriate data collection for drug approval. Also, there must be frequent communication (written) from the FDA about problems relating to the design of proposed clinical trials and biomarkers use. If the drug meets the relevant criteria, it becomes eligible for Accelerated Approval and Priority Review. The last step involves carrying out of Rolling Review, which necessitates the drug company to submit their New Drug Application or BLA to FDA for final review. That constitutes the whole process in Fast track (FDA, 2018).
Medical Conditions which use Fast Track Drugs
As mentioned above, fast track is aimed at fulfilling an unmet medical need. Some of the medical conditions which use this designation include diseases which have reached a terminal stage, e.g. metastasized cancer. Also, a medical condition which causes severe physical or mental as well impairments like the likes of Down Syndrome, HIV/Aids, total blindness total deaf conditions or Alzheimer's can use fast track designation. In circumstances where veterans obtain physical injury while on active duty or even on leave is also viable to receive fast track designated drugs. Particular cases, e.g. an infant being born with low-birth weight, can also merit expedited processing (AARP, 2020).
REFERENCES
AARP. (2020). Which conditions does SSA consider for fast-track decisions? https://www.aarp.org/retirement/social-security/questions-answers/ssa-disability-fast-track-decision.html
FDA. (2018, January 4). Fast track. U.S. Food and Drug Administration. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
FDA. (2020, January 24). Fast track designation requests. U.S. Food and Drug Administration. https://www.fda.gov/drugs/ind-activity/fast-track-designation-requests
Guillermo Carabeo
The fast track regulation process
All new drugs need to demonstrate that they can provide better benefits than their potential risks in a process that is known as a favorable benefit-risk ratio. When developing long and detailed drugs, this has to be used as the premise, and the process is regulated by fast track. Before any drug is released for use, it must follow all the regulation and guidelines that the fast track sets that. In most cases, a lot of regulation is made when dealing with a drug that is first available treatment and the drug is believed to have better advantages as compared to the previous therapies (Carter, 2019). To ensure that such drugs are available for use at a fast pace, the FDA has established four processes that need to be adhered to especially for ensuring that the drugs are made more rapidly available. These processes are the
i) Fast track process
This process is majorly designed to help facilitating the development of the drug as well as ensuring that FDA processes of reviewing the drug are accelerated, especially when dealing with a more severe drug.
ii) Breakthrough therapy
This process is designed to ensure that there is accelerated development as well as a review of drugs designed to deal with serious conditions especially when clinical evidence shows that there is a potential improvement especially when comparing with the available therapy (Carter, 2019)
.
iii) Accelerated approval
The FDA brought out the accelerated approval in 1992 and the congress in 2012, passed the Food and Drug Administration safety innovation act that gave power to the FDA to ensure that there is accelerated approval to drugs that deals with severe conditions and those that are meant to a dire medical need.
iv) Priority review
Through the priority review, the FDA can take actions on any applications in only six months when compared with the standard ten months (Carter, 2019). The FDA is directed by the priority review designation to ensure that it directs its attention and resources to drug evaluation that is likely to bring significant effectiveness and safety of the treatments, diagnosis as well as serious conditions prevention especially when comparing to other known applications.
Medical conditions warrant the use of “Fast Track” drugs.
The fast track is only designed to deal with severe conditions. Although the criteria for determining whether a situation is critical or nor is very subjective, certain medical conditions have universally being agreed to be dangerous (Katsanos, 2016). One of the medical condition that has been decided to be severe and thus warrant of fast track is cancer. All types of cancers warrant fast track, including all lymphomas. The other that warrant fast track is HIV/Aids, which has also been classified as a severe condition affecting the whole globe.
References
Cyranoski, D. (2017). China announces plans to fast-track drug approval. Nature. doi:10.1038/nature.2017.22888
Carter, C. (2019) The FDA drug approval process for serious medical conditions: VHL alliance. (2019, August 12). Retrieved from https://www.vhl.org/fda-drug-approval/
Katsanos, K. H. (2016). Fast-track drug approval in inflammatory bowel diseases. Annals of Gastroenterology. doi:10.20524/aog.2016.0051
Maritza Leon
Fast Track Drugs
The United States Food and Drug Administration (FDA) is an agency of the government under the department of health. The Food and Drug Administration is responsible for protecting the public health via inspection of safety in products that re consumed by human beings to prevent causing harm to their health (Papadimitriou & Butler, 2017). In the medical field FDA, I responsible for ensuring that the drugs and other pharmaceutical products are fit for human consumption. The FDA is the only organization that is authorized to Fast Track the process of developing certain medications to make them available in the market for use or purchase by the public.
The fast track process is a systematic and procedural, and it is guided by rules and regulations to ensure that the product being fast-tracked is safe for use. Before a drug company develops a drug for human consumption, it must conduct thorough research on the components used to create the medication to ensure that it will not cause harm or injuries for the patient. In the scenario that the company wants the drug to be fast-tracked, it requests the FDA (Papadimitriou & Butler, 2017). After the acceptance of the request, the FDA takes medicine and reviews it to ensure that it is safe for human consumption and that it has no adverse side effects on its users. If the drug is safe and is intended to cure a severe disease that has affected many people, then the company is given the green light to continue with the development, manufacture and distribution of the drug.
Before FDA orders the fast track of any drug, it must have been proven to cure, control or manage a serious condition that is threatening the public (Papadimitriou & Butler, 2017). A good example is the COVID 19 or the Coronavirus that has been declared a pandemic and has affected the whole world. If any drug company develops a drug that can cure or manage the virus, then the FDA can give the authority to fast track the production of that drug to ensure that a solution is reached as soon as possible. The conditions that warrant the Fast Track of a drug are severe conditions that cause massive death and has affected the majority of the population.
Papadimitriou, L., & Butler, J. (2017). “Fast Track” Development and Approval Process for Heart Failure Therapeutics. Clinical Pharmacology & Therapeutics, 102(2), 184-186.
